Figure 1From: Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?Illustrative figures of TIMP1 staining. Panel A: Homogenous staining. Panel B: Heterogeneous staining.Back to article page